Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) insider Timothy Moran sold 3,192 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $29.56, for a total value of $94,355.52. Following the sale, the insider owned 63,153 shares in the company, valued at approximately $1,866,802.68. This trade represents a 4.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kestra Medical Technologies Stock Performance
Shares of Kestra Medical Technologies stock opened at $28.80 on Friday. Kestra Medical Technologies, Ltd. has a one year low of $17.34 and a one year high of $31.91. The company has a market cap of $1.72 billion, a PE ratio of -10.79 and a beta of 0.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.69 and a current ratio of 4.69. The business has a 50-day simple moving average of $26.96 and a 200-day simple moving average of $23.99.
Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last released its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). The firm had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. On average, equities research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current fiscal year.
Hedge Funds Weigh In On Kestra Medical Technologies
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sterling Capital Management LLC raised its holdings in Kestra Medical Technologies by 834.0% during the third quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock worth $25,000 after purchasing an additional 784 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kestra Medical Technologies in the 3rd quarter valued at $353,000. Quantinno Capital Management LP purchased a new position in shares of Kestra Medical Technologies in the 1st quarter valued at $431,000. California State Teachers Retirement System grew its position in shares of Kestra Medical Technologies by 39.2% in the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after buying an additional 7,844 shares during the last quarter. Finally, Spartan Wealth Advisory Services LLC purchased a new position in shares of Kestra Medical Technologies in the 1st quarter valued at $603,000.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on KMTS shares. JPMorgan Chase & Co. began coverage on shares of Kestra Medical Technologies in a report on Monday, August 10th. They issued an “overweight” rating and a $30.00 price objective on the stock. Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Sunday. Weiss Ratings raised Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Finally, BTIG Research reaffirmed a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $29.00.
Check Out Our Latest Report on Kestra Medical Technologies
Kestra Medical Technologies Company Profile
Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.
The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.
Featured Articles
- Five stocks we like better than Kestra Medical Technologies
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
